Implementing precision medicine initiatives in the clinic: a new paradigm in drug developmentHollebecque, Antoinea; Massard, Christophea; Soria, Jean-Charlesa,b,cCurrent Opinion in Oncology: May 2014 - Volume 26 - Issue 3 - p 340–346 doi: 10.1097/CCO.0000000000000077 INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review With the recent advances in genome sequencing technology, greater knowledge of cancer biology allows the identification of different molecular alterations in tumor samples from patients with advanced cancer, some of which are promising potential therapeutic targets. This review highlights the different methods for molecular screening, examines the recent success and preliminary precision medicine programs’ results. Challenges and perspectives of this approach are discussed. Recent findings The emergence of high-throughput technologies has allowed the stratification of most common diseases into rare molecular segments. The recent success of predictive biomarkers showed that molecular screening has become essential in the development of drugs in early clinical trials. Several prospective trials are ongoing worldwide with very promising results. Summary Characterization of the genomic alterations in cancer patients is now critical to better select molecular-targeted therapies and to accelerate the drug development process in phase I/II. High-throughput analysis is feasible in daily practice, and allows enrichment of phase I trials in molecularly selected patients. aDrug Development Department (DITEP: Département d’Innovations Thérapeutiques et Essais Précoces) bInserm Unit U981, Gustave Roussy Cancer Campus, Villejuif cFaculté du Kremlin Bicêtre, Université Paris Sud, France Correspondence to Dr Antoine Hollebecque, Drug Development Department (DITEP: Département d’Innovations Thérapeutiques et Essais Précoces), Gustave Roussy, Cancer Campus, Grand Paris, 94805 Villejuif, France. Tel: +33 1 42 11 43 38; fax: +33 1 42 11 52 17; e-mail: email@example.com © 2014 Lippincott Williams & Wilkins, Inc.